


## Sucnamostat hydrochloride

<b>Cat. No.:</b>	HY-132841A		
<b>Molecular Formula:</b>	C <sub>22</sub> H <sub>23</sub> ClN <sub>4</sub> O <sub>8</sub>		
<b>Molecular Weight:</b>	506.89		
<b>Target:</b>	Enteropeptidase		
<b>Pathway:</b>	Metabolic Enzyme/Protease		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : ≥ 125 mg/mL (246.60 mM)  
 \* "≥" means soluble, but saturation unknown.

Concentration	Solvent	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	1.9728 mL	9.8641 mL	19.7281 mL
	5 mM	0.3946 mL	1.9728 mL	3.9456 mL
	10 mM	0.1973 mL	0.9864 mL	1.9728 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

Sucnamostat (SCO-792) hydrochloride is an orally active and reversible enteropeptidase inhibitor with IC<sub>50</sub>s of 4.6 nM and 5.4 nM for rat enteropeptidase and human enteropeptidase, respectively. Sucnamostat hydrochloride can slowly dissociate from enteropeptidase in vitro and inhibit protein digestion in vivo<sup>[1]</sup>.

#### IC<sub>50</sub> & Target

IC<sub>50</sub>: 4.6 nM (rat enteropeptidase), 5.4 nM (human enteropeptidase)<sup>[1]</sup>

#### In Vivo

Sucnamostat hydrochloride (10 and 30 mg/kg; PO, single dosage) effectively and dose-dependently inhibits plasma branched-chain amino acids (BCAA) elevations induced by oral protein dosing in rats<sup>[1]</sup>.  
 Pharmacokinetic Parameters of Sucnamostat hydrochloride in male Sprague-Dawley rats<sup>[1]</sup>

	PO (10 mg/kg)	IV (2 mg/kg)
C <sub>max</sub> (ng/mL)	6.60 ± 1.36	564 ± 58

---

$T_{\max}$ (h)	$1.7 \pm 0.6$	
AUC <sub>0-24</sub> (ng/mL·h)	$54.1 \pm 7.5$	$303 \pm 23$
AUC <sub>inf</sub> (ng/mL·h)	$49.8 \pm 5.4$	$304 \pm 30$
Vd <sub>SS</sub> (mL/kg)		$1290 \pm 299$
CL <sub>p</sub> (mL/min/kg)		$663 \pm 66$
bioavailability (%)	0.4	

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

---

## REFERENCES

---

[1]. Sasaki M, et al. Discovery and characterization of a small-molecule enteropeptidase inhibitor, SCO-792. Pharmacol Res Perspect. 2019 Sep 4;7(5):e00517.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA